<DOC>
	<DOCNO>NCT02232581</DOCNO>
	<brief_summary>The primary objective determine mean change HIV viral load baseline Week 4 compare placebo 4 week treatment highly experienced HIV-infected patient . Secondary objective determine ( 1 ) tolerability , hematologic hepatic safety different dos alovudine ( 2 ) effect baseline nucleoside genotypic susceptibility virologic response 4 week alovudine administration</brief_summary>
	<brief_title>Study Determine Antiviral Activity Safety Alovudine Nucleoside-experienced HIV-infected Subjects Experiencing Virologic Failure</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>Alovudine</mesh_term>
	<mesh_term>Dideoxynucleosides</mesh_term>
	<criteria>Signed informed consent trial procedure HIV1 infect male female ≥18 year age Screening genotypic resistance report indicate two follow nucleoside reverse transcriptase inhibitor ( NRTI ) resistance mutation : 41 , 67 , 70 , 210 215 Stable NRTI regimen without stavudine zidovudine least 6 week screen stable antiretroviral ( ARV ) background treatment 3 month screen HIV1 viral load ≥1000 copies/mL &lt; 75,000 copies/mL screen Change viral load previous test within 3 month screen , use local laboratory routine test , screen test &lt; 1.0 log10 copies/mL Acceptable medical history , assess investigator Current stable ARV medication regimen screen ( Visit 1 ) Visit 2 ARV medication naïve Patients recent drug holiday , define ARV medication least 7 consecutive day within previous 3 month Female patient childbearing potential : positive serum pregnancy test breast feeding , plan become pregnant , willing use barrier method contraception Prior alovudine use Use investigational medication within 30 day study entry trial Use immunomodulatory drug within 3 month study entry trial ( e.g . interferon , cyclosporine , hydroxyurea , interleukin2 ) Current use rifampin , rifabutine , isoniazid , pyrazinamide , stavudine , zidovudine , ganciclovir , chronic use hepatotoxic drug , antitumour therapy probenecid Laboratory value : Neutrophils Grade 2 great abnormality Hemoglobin Grade 2 great abnormality Platelets : Grade 2 great abnormality Creatinine ≥1.25 Upper limit normal ( ULN ) Lipase Grade 1 great abnormality Alanine aminotransaminase ( ALT ) Aspartate aminotransaminase ( AST ) Grade 2 great abnormality Direct bilirubin Grade 1 great abnormality CD4 ≤50 cells/mm3 Hepatitis B ( +HBsAg +HBcAB ) C +Hepatitis C virus ( +HCV AB ) coinfection , chronic hepatitis , ongoing hepatitis pancreatitis Any new active AIDSdefining event within 30 day study entry Inability adhere requirement protocol , include active substance abuse assess investigator In opinion investigator , likely survival le 6 month underlying disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>